Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-cash Items (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non-cash Items for 12 consecutive years, with $115071.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 82.14% to $115071.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $115071.0, a 82.14% decrease, with the full-year FY2025 number at $236055.0, up 70575.15% from a year prior.
  • Non-cash Items was $115071.0 for Q4 2025 at PharmaCyte Biotech, down from $175562.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $1.8 million in Q1 2021 to a low of $97.35 in Q2 2021.
  • A 5-year average of $246691.8 and a median of $145316.5 in 2025 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 1387400.0% in 2021; the steepest drop was 99.98% in 2021.
  • PharmaCyte Biotech's Non-cash Items stood at $333.0 in 2021, then skyrocketed by 11192.19% to $37603.0 in 2022, then surged by 644.09% to $279802.0 in 2023, then surged by 130.22% to $644161.0 in 2024, then crashed by 82.14% to $115071.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Non-cash Items are $115071.0 (Q4 2025), $175562.0 (Q3 2025), and $236055.0 (Q2 2025).